tradingkey.logo

Edwards Lifesciences Corp

EW

76.050USD

-1.520-1.96%
Close 09/15, 16:00ETQuotes delayed by 15 min
44.71BMarket Cap
10.78P/E TTM

Edwards Lifesciences Corp

76.050

-1.520-1.96%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated2025-09-15

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
43 / 207
Overall Ranking
155 / 4724
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 35 analysts
Buy
Current Rating
88.401
Target Price
+13.96%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 174.30.
Fairly Valued
The company’s latest PE is 10.91, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 528.14M shares, decreasing 3.77% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 69.74M shares of this stock.

Financial Health

Currency: USD Updated2025-09-15

The company's current financial score is 7.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.15. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 1.41B, representing a year-over-year decrease of 11.61%, while its net profit experienced a year-over-year decrease of 1.73%.

Score

Industry at a Glance

Previous score
7.00
Change
2.07

Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

8.06

Operational Efficiency

9.57

Growth Potential

10.00

Shareholder Returns

7.71

Company Valuation

Currency: USD Updated2025-09-15

The company’s current valuation score is 1.80, which is lower than the Healthcare Equipment & Supplies industry's average of 2.15. Its current P/E ratio is 11.61, which is -4.12% below the recent high of 11.13 and 7.63% above the recent low of 10.72.

Score

Industry at a Glance

Previous score
1.80
Change
0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 43/207
No Data

Earnings Forecast

Currency: USD Updated2025-09-15

The company’s current earnings forecast score is 7.43, which is lower than the Healthcare Equipment & Supplies industry's average of 7.66. The average price target for Edwards Lifesciences Corp is 88.00, with a high of 101.00 and a low of 72.00.

Score

Industry at a Glance

Previous score
7.43
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 35 analysts
Buy
Current Rating
88.401
Target Price
+13.96%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

94
Total
4
Median
7
Average
Company name
Ratings
Analysts
Edwards Lifesciences Corp
EW
35
Boston Scientific Corp
BSX
36
Intuitive Surgical Inc
ISRG
34
Veeva Systems Inc
VEEV
32
Thermo Fisher Scientific Inc
TMO
31
Danaher Corp
DHR
26
1
2
3
...
19

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated2025-09-15

The company’s current price momentum score is 8.95, which is higher than the Healthcare Equipment & Supplies industry's average of 7.47. Sideways: Currently, the stock price is trading between the resistance level at 83.41 and the support level at 77.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.58
Change
-0.42

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-1.230
Neutral
RSI(14)
31.242
Neutral
STOCH(KDJ)(9,3,3)
8.583
Oversold
ATR(14)
1.475
High Vlolatility
CCI(14)
-166.498
Sell
Williams %R
99.101
Oversold
TRIX(12,20)
0.017
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(5)
Neutral(0)
Buy(1)
Indicators
Value
Direction
MA5
77.942
Sell
MA10
79.481
Sell
MA20
80.101
Sell
MA50
78.816
Sell
MA100
77.427
Sell
MA200
74.602
Buy

Institutional Confidence

Currency: USD Updated2025-09-15

The company’s current institutional recognition score is 7.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. The latest institutional shareholding proportion is 89.95%, representing a quarter-over-quarter decrease of 1.41%. The largest institutional shareholder is The Vanguard, holding a total of 69.74M shares, representing 11.88% of shares outstanding, with 1.72% increase in holdings.

Score

Industry at a Glance

Previous score
7.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
The Vanguard Group, Inc.
Star Investors
68.94M
+0.10%
BlackRock Institutional Trust Company, N.A.
32.28M
+1.71%
State Street Global Advisors (US)
25.78M
-0.10%
JP Morgan Asset Management
16.37M
+52.12%
Wellington Management Company, LLP
29.13M
-12.27%
Citadel Advisors LLC
13.38M
+42.09%
Geode Capital Management, L.L.C.
12.68M
-7.11%
Jennison Associates LLC
10.09M
+34.31%
Walter Scott & Partners Ltd.
9.06M
-3.69%
1
2

Risk Assessment

Currency: USD Updated2025-09-15

The company's beta value is 1.07. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
6.61
Change
0
Beta vs S&P 500 index
1.06
VaR
+2.66%
240-Day Maximum Drawdown
+11.97%
240-Day Volatility
+29.61%
Return
Best Daily Return
60 days
+5.54%
120 days
+6.63%
5 years
+9.38%
Worst Daily Return
60 days
-2.28%
120 days
-4.96%
5 years
-31.34%
Sharpe Ratio
60 days
+0.82
120 days
+0.90
5 years
+0.12
Risk Assessment
Maximum Drawdown
240 days
+11.97%
3 years
+37.53%
5 years
+54.32%
Return-to-Drawdown Ratio
240 days
+1.50
3 years
-0.09
5 years
-0.03
Skewness
240 days
+1.23
3 years
-4.81
5 years
-3.43
Volatility
Realised Volatility
240 days
+29.61%
5 years
+34.33%
Standardised True Range
240 days
+2.25%
5 years
+2.91%
Downside Risk-Adjusted Return
120 days
+148.23%
240 days
+148.23%
Maximum Daily Upside Volatility
60 days
+20.99%
Maximum Daily Downside Volatility
60 days
+14.12%
Liquidity
Average Turnover Rate
60 days
+0.71%
120 days
+0.76%
5 years
--
Turnover Deviation
20 days
-17.23%
60 days
-9.30%
120 days
-1.82%

Peer Comparison

Healthcare Equipment & Supplies
Edwards Lifesciences Corp
Edwards Lifesciences Corp
EW
6.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
7.98 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
WST
7.79 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
7.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
7.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Merit Medical Systems Inc
Merit Medical Systems Inc
MMSI
7.49 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI